Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma



Similar documents
Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed

Flow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy.

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

for Leucocyte Immunophenotyping Leukaemia Diagnosis Interpretation All Participants Date Issued: 08-September-2014 Closing Date: 26-September-2014

Non-Hodgkin s Lymphoma

Malignant Lymphomas and Plasma Cell Myeloma

Pathology No: SHS-CASE No. Date of Procedure: Client Name Address

Utility of flow cytometric κ and λ light chain analysis of peripheral blood

Leukemias and Lymphomas: A primer

Outline of lecture. Disclosures. Current Issues in Practical Hematopathology: Diagnosis of Bone Marrow Lymphomas

DELPHI 27 V 2016 CYTOMETRY STRATEGIES IN THE DIAGNOSIS OF HEMATOLOGICAL DISEASES

Hematology Morphology Critique

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

Lymphoma Diagnosis and Classification

Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.

The NIAID Flow Cytometry Advisory Committee; the Guidelines Subcommittee

Flow Cytometry A Guide for Data Analysis

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital

Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH

Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham

International Beryllium Conference, Montreal, Canada March 10, 2005

Waldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May Morie Gertz MD, MACP

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic

WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED?

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015

PERIPHERAL SMEARS: THE PRIMARY DIAGNOSTIC TOOL PART II IRMA PEREIRA, MT(ASCP)SH

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY

Stepcount. Product Description: Closed transparent tubes with a metal screen, including a white matrix at the bottom. Cat. Reference: STP-25T

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

Anaplastic large cell lymphoma (ALCL) accounts for approximately

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

Reference Range: mmol/l (arterial) mmol/l (venous) CPT Code: 83605

Methodology for Automatic Classification of Atypical Lymphoid Cells from Peripheral Blood Cell Images

Immunohistochemical classification of malignant lymphomas

Hematopathology VII Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, And Hairy Cell Leukemia

Supplementary appendix

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

Oncology Best Practice Documentation

Genomic Analysis of Mature B-cell Malignancies

Standardization, Calibration and Quality Control

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data

Diagnostika onkohematologických ochorení pomocou prietokovej cytometrie Jozef Smolka Beckman Coulter Slovenská republika s.r.o.

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Mantle Cell Lymphoma Understanding Your Treatment Options

Large Cell Lymphoma Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma A Flow Cytometric Analysis of Seven Cases

Fluorescence Compensation. Jennifer Wilshire, PhD

Chronic lymphocytic EBMT Slideleukemia. University of Heidelberg, Germany March 22, The European Group for Blood and Marrow Transplantation

CD5-positive, Small B-Cell Lymphoproliferative Disorders: Aberrant Findings of CLL/SLL and MCL

Update on Diagnosis and Treatment of Lymphoma

Multiple Myeloma and Colorectal Cancer

123count ebeads Catalog Number: Also known as: Absolute cell count beads GPR: General Purpose Reagents. For Laboratory Use.


Novel Use of the BD FACS TM SPA to Automate Custom Monoclonal Antibody Panel Preparations for Immunophenotyping

INFECTIOUS MONONUCLEOSIS DIAGNOSTIC POTENTIALS

Application Note 10. Measurement of Cell Recovery. After Sorting with a Catcher-Tube-Based. Cell Sorter. Introduction

Multicolor Flow Cytometry: Setup and Optimization on the BD Accuri C6 Flow Cytometer

Hairy Cell Leukemia Facts

Immunophenotyping. Alberto Orfao, MD, PhD

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.

Immuno-Oncology Model Application in the Preclinical Treatment Setting

Chromosome 6 Abnormalities Associated with Prolymphocytic Acceleration in Chronic Lymphocytic Leukemia* f

Treatment of low-grade non-hodgkin lymphoma

Multicolor Bead Flow Cytometry Standardization Heba Degheidy MD, PhD, QCYM DB/OSEL/CDRH/FDA Manager of MCM Flow Cytometry Facility

Principles of Flowcytometry

BD FACSCalibur. The flow cytometer for your routine cell analysis needs

Using the BD TM Cytometer Setup and Tracking (CS&T) System for Instrument Characterization and Performance Tracking

CAR T cell therapy for lymphomas

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.

Things You Don t Want to Miss in Multiple Myeloma

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:

Frequency of NHL Subtypes in Adults

David Loew, LCL MabThera

NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010

Canine lymphoproliferative disorders often present

Welcome to More Choice BD Analyte Specific Reagent (ASR) Catalog

2 Year ( ) CLL/SLL Research Initiative CLL/SLL Collaborative Grant

Introduction to Flow Cytometry

WHOLE BLOOD LYSING SOLUTION FOR FLOW CYTOMETRIC APPLICATIONS

Too Many B Cells: Chronic Lymphocytic Leukemia and the Role of Flow Cytometry

Corporate Medical Policy

Summary & Conclusion

Introduction to Flow Cytometry

Transcription:

Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, DCS, NCI,NIH DEPARTMENT OF HEALTH & HUMAN SERVICES

Flow Cytometric Analysis of Hematolymphoid Neoplasia Standard of care-not research Guidelines available for medical indications Plays a vital role in diagnosis and subclassification Davis et al.. 2006 Bethesda International Consensus Recommendations on the Flow Cytometric Immunophenotypic Analysis of Hematolymphoid Neoplasia: Medical Indications, Clinical Cytometry. 72B:S5-S13, 2007

Flow Cytometric Diagnosis of Chronic Lymphocytic Leukemia (CLL) CLL is the most common leukemia in the western world Diagnosis is routinely made by a combination of flow cytometry, WBC and review of clinical history Flow cytometric diagnosis is accepted medical practice

Chronic Lymphocytic Leukemia (CLL) CLL Incidence: by country

Chronic Lymphocytic Leukemia (CLL) Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute Working Group (NCI WG) 1996 guidelines: The diagnosis of CLL requires the presence of more than or equal to 5x 10 9 /L B lymphocytes (5000/µL) in the peripheral blood for the duration of at least 3 months. Clinical history is relevant Blood. 2008;111:5446 5456)

Flow Cytometric Diagnosis of CLL : If detect by flow cytometry the presence of monoclonal B-cells with appropriate immunophenotype in the peripheral blood and at least 5x 10 9 /L B lymphocytes (5000/µL)*- Diagnosis is CLL If less than 5x 10 9 /L B lymphocytes (5000/µL)- Diagnosis is Monoclonal B-Cell Lymphocytosis Absolute lymphocyte count elevated: Monoclonal lymphocytosis with clinical lymphocytosis: Absolute lymphocyte count not elevated: Low count monoclonal lymphocytosis * duration of at least 3 months Clinical history and WBC results relevant

Flow Cytometric Diagnosis of CLL: Not a Chemistry Test But a Clinical Diagnosis SF13 228 pb_01_s-1.fcs SF13 211 pb_01_s-1.fcs 406 314 305 236 Count 203 54% B-cells Count 157 54% B-cells 102 0 10 0 10 1 CD19 PE HCL 79 0 10 0 10 1 CD19 PE CLL SF12 904 pb_01_s-1.fcs SF13 198 pb_01_s-1.fcs 422 153 Count 317 211 106 48% B-cells Polyclonal Count 115 77 38 46% B-cells Polyclonal 0 10 0 10 1 CD19 PE 0 10 0 10 1 CD19 PE Need more than a B-cell lymphocytosis for Diagnosis of CLL

Differential Diagnosis in CLL: Mantel Cell lymphoma Splenic Lymphoma with Villous Lymphocytes (SLVL) Lymphoplasmacytic lymphoma Follicular Lymphoma PLL HCL And if not determining lymphocytosis is B-cellother non-hodgkin s lymphomas, including T- cell.

Flow Cytometric Diagnosis of CLL: Not a Chemistry Test But a Clinical Diagnosis SF13 211 pb_08_b-5 new.fcs Can we just count CD5+ B-cells? SF12 324 pb_08_b-6+ K-p APC.fcs SF13 228 pb_08_b-5 new.fcs SF12 904 pb_08_b-6+ K-p.fcs CD5 PerCP Cy55 CLL CD5 PerCP Cy55 MCL CD5 PerCP Cy55 HCL CD5 PerCP Cy55 Polyclonal 103 104 105 103 104 105 103 104 105 103 104 105 SF13 211 pb_08_b-5 new.fcs SF12 904 pb_08_b-6+ K-p.fcs SF12 904 pb_08_b-6+ K-p.fcs Lambda-p FITC CD5 PerCP Cy55 Gate 222 Lambda-p FITC Kappa-p APC 103 104 105 103 104 105 Kappa-p APC 103 104 105

Flow Cytometric Diagnosis of CLL: Similar to Looking at H&E Slide CLL with vaguely nodular growth centers Follicular Lymphoma Reactive

Flow Cytometric Diagnosis of CLL : Appropriate Immunophenotype 105 105 105 CD19+CD5+ CD5 v450 104 103 CD23 APC 104 103 CD81 FITC 104 103 CD23+ Dim to negative CD81 Dim CD20, dim CD22 102 102 103 104 105 102 102 103 104 105 102 102 103 104 105 Dim to negative CD79b Monoclonal 105 105 105 CD22 PE 104 103 CD79b PE 104 103 Lambda-m PE 104 103 CLL 102 102 102 CD20 AH7 102 103 104 105 102 103 104 105 Kappa-m FITC 102 103 104 105

Flow Cytometric Diagnosis of CLL : Appropriate Immunophenotype CD5 APC CD23 APC CD81 FITC CD19+CD5+ Dim Partial CD23+ Moderate CD81 Moderate CD20&CD22 Moderate CD79b Monoclonal CD22 PE CD79b APC Lambda-m PE MCL CD20 AH7 Kappa-m FITC

CLL Diagnosis is Routinely Performed by Flow Cytometry: 5x 10 9 /L B-cells (5000/µL) At least 3 months duration Monoclonal Appropriate immunophenotype (CD19+, CD5+, CD23+, dim CD20+, dim CD22+, dim to negative CD79b, dim to negative CD81, CD43+, dim CD45+, dim surface immunoglobulin Diagnosis made by medical professional based upon identification of abnormal pattern and correlating this with history and other test results (WBC)

Flow Cytometry Used in Diagnosis and Sub-Classification of B- LPD Differentiation of reactive from clonal Sub-classification of CD5+ B-cell neoplasms: CLL, MCL, PLL, LCL, HCL, FL, Sub classification of CD10+ B-cell neoplasms: FL, Burkitt s. LCL, MCL, HCL Sub-classification of B-cell neoplasms with hairy/villous cytoplasmic borders HCL, HCLv, SLVL

Differentiation of reactive from clonal 422 SF12 904 pb_01_s-1.fcs Count 317 211 48% B-cells 106 0 10 0 10 1 CD19 PE SF12 904 pb_08_b-6+ K-p.fcs SF12 904 pb_08_b-6+ K-p.fcs SF12 904 pb_08_b-6+ K-p.fcs CD5 PerCP Cy55 CD5 PerCP Cy55 Gate 222 Lambda-p FITC 103 104 105 103 104 105 Kappa-p APC 103 104 105

Subclassification of B- Cell Neoplasms: CD5+ MCL: +CD5, +CD19, - CD23 (may be dim+), moderate CD20, CD22, sig, CD79b, CD81, CD45, CLL: +CD5, +CD19, +CD23, dim CD20, CD22, sig, CD79b, CD81, CD45 PLL and LCL CD5 CD5 CD19 CD19

Subclassification of B- Cell Neoplasms: CD10 Positivity FL: + CD10, dim CD19, +CD20, +CD22, +sig, +/-CD23, -CD5, -CD25, -CD11c, -CD103 Burkitt s: +CD10, moderate CD19, +CD20, +CD22, +sig, -CD23, -CD5 ALL:Immature +CD10, dim CD19, +CD22, +/-CD20, +TdT, -sig, +/-CD34 LCL and MCL CD10 CD10 CD19 CD19

Subclassification of B- Cell Neoplasms: Hairy/Villous Cytoplasmic Borders HCL + CD19, Bright CD20, Bright CD22, Bright CD25, Bright CD11c, CD103, CD123 HCLv + CD19, Bright CD20, Bright CD22, ++CD11c(can be moderate or dim), +CD103, - CD25, - or dimcd123 SLVL + CD19, Moderate CD20, Moderate CD22, +/- CD11c (dim when +), CD25-, CD103-, CD123- CD11c CD11c CD20 CD20

HCL CD19 PerCP Cy55 CD22 1:1 PE CD11c APC CD25 PE CD123 PE CD3 APC CD20 PerCP CD103 FITC CD20 PerCP CD20 PerCP HCLv CD19 PerCP Cy55 SLVL CD3 APC CD22 1:1 PE CD20 PerCP CD11c APC CD103 FITC CD25 PE CD20 PerCP CD123 PE CD20 PerCP CD19 PerCP Cy55 CD3 APC CD22 1:1 PE CD20 PerCP CD11c APC CD103 FITC CD25 PE CD20 PerCP CD123 PE CD19 PerCP Cy 55

Summary Flow cytometry is routinely used for diagnosis and sub-classification of B-cell neoplasia The diagnosis is made by a medical professional with intimate knowledge of normal immunophenotypic patterns Diagnosis is based upon recognition of an abnormal pattern, not a single value, similar to evaluation of morphology. Flow cytometric results are correlated with clinical history and the results of other tests for the diagnosis